NCT01390428View on ClinicalTrials.gov

Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Grazoprevir (MK-5172-013)

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 28, 2011

Primary Completion Date

September 5, 2014

Study Completion Date

September 12, 2014

Conditions
Hepatitis C
Interventions
DRUG

Grazoprevir

Part 1: oral morning dose of 200 mg daily for 10 days Part 2: oral morning dose of 100 mg daily for 10 days Part 3: oral morning dose of 50 mg daily for 10 days

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01390428 - Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Grazoprevir (MK-5172-013) | Biotech Hunter | Biotech Hunter